<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00680628</url>
  </required_header>
  <id_info>
    <org_study_id>01-08-01A</org_study_id>
    <nct_id>NCT00680628</nct_id>
  </id_info>
  <brief_title>Clot Dissolving Treatment for Blood Clots in the Lungs</brief_title>
  <official_title>Randomized Trial of Tenecteplase to Treat Severe Submassive Pulmonary Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeffrey Kline</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carolinas Healthcare System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if tenecteplase plus enoxaparin is safe and
      effective in the treatment of patients with severe submassive pulmonary embolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project is a phase III, six-center, randomized trial of tenecteplase to treat severe
      submassive (systolic blood pressure &gt;90 mm Hg) pulmonary embolism (PE). &quot;Severe&quot; requires one
      of the following predictors of a adverse outcome: right ventricular (RV) hypokinesis on
      echocardiography, hypoxemia (pulse oximetry reading &lt;95%, &lt;1000 feet above sea level), serum
      troponin I (abnormal at local threshold) or brain natriuretic peptide concentration &gt;90 pg/mL
      (or NT proBNP &gt;900 pg/mL). Patients from the emergency department or inpatients can be
      enrolled within 24 hours of a diagnostic positive CT angiography. After informed consent,
      eligible patients will be randomized to the study or placebo arm. All patients will a receive
      a 1mg/kg enoxaparin, SQ followed by a syringe prepared in pharmacy containing either a body
      weight-adjusted dose of tenecteplase or a 0.9% saline placebo, given IV push. Patients will
      be followed for five days post-treatment for composite acute adverse outcomes: PE-related
      (death, any ACLS intervention, circulatory shock, respiratory failure, need for vasopressors
      with organ dysfunction) and hemorrhage-related (intracranial or intraspinal hemorrhage and
      any other hemorrhage requiring transfusion, surgical or endoscopic intervention or a
      hemostatic drug). Survivors will return at three months for assessment of a delayed adverse
      outcomes of death or cardiopulmonary functional limitation (CFL): interval medical care for
      dyspnea + RV dysfunction or pulmonary hypertension on echo + either a NYHA score ≥3 or a 6
      minute walk distance &lt;330 m. Together, the acute and delayed outcomes represent composite
      serious adverse outcomes (SAOs). We hypothesize an absolute 20% reduction in composite
      serious adverse outcomes in the study arm compared with the placebo arm. The six hospitals
      represent geographic diversity: Boston, Charlotte, Chicago, Denver, New Haven, and
      Springfield, MA. To help maintain balance between sites, the six sites will each enroll a
      maximum of 40 patients until the sample size of N=200 is reached, which allows the 20% effect
      size to be tested at α =0.05 and β=0.20 with 15% loss to follow-up. The study will employ an
      intent-to treat analysis. Secondary endpoints include recurrent venous thromboembolism within
      three months, scores from two validated quality of life questionnaire (VEINES-QOL and
      SF-36TM) at three months. Human subject safety include requirement that a study MD verify the
      presence of all inclusion and absence of exclusions in real-time, a method to allow
      unblinding to the clinical care team, an independent DSMB that will perform 6 interim
      analyses and will enforce predefined stopping criteria for either safety or efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI changed institution and impossible to solve problem with contract's sites
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Cardiogenic Shock or Respiratory Failure From Pulmonary Embolism and Number of Patietnts With Major Hemorrhage</measure>
    <time_frame>1,2,3,4, and 5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number With Functional Cardiopulmonary Limitations Assessed With a Composite Measurement (Six Minute Walk Distance, Right Ventricular Function and Quality of Life Score on the SF-36)</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number With Recurrent Venous Thromboembolism and/or Severe Post-phlebitic Syndrome</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline + Enoxaparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenecteplase + Enoxaparin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenecteplase + Enoxaparin</intervention_name>
    <description>Enoxaparin: 1 mg/kg within 12 hours before receiving tenecteplase.Subsequently, patients will receive 1 mg/kg enoxaparin SQ Q12 hours until discontinuation is clinically indicated.
Tenecteplase:will be administered using a tiered-dosing schedule according to patient weight: &lt;60Kg=30mg; ≥60Kg to &lt;70Kg=35mg; ≥70Kg to &lt;80Kg=40mg; ≥80Kg to &lt;90Kg=45mg; ≥90Kg=50mg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% Saline + Enoxaparin</intervention_name>
    <description>Enoxaparin: 1 mg/kg within 12 hours before receiving saline.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pulmonary vascular imaging positive for PE within the previous 24 hours

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study

          -  Age &gt;17 years

          -  Evidence of severe PE: RV hypokinesis on echocardiography, abnormal troponin I or T
             (any non-normal including indeterminate values, using local reference thresholds) or
             BNP measurement &gt;90 pg/mL or NT proBNP &gt;900 pg/ml (not more than 6 hours prior to CT
             angiography and not more than 30 hours before enrollment) or a pulse oximetry reading
             &lt;95% within previous two hours (&lt;93% in Denver).

        Exclusion Criteria:

          -  Systolic blood pressure &lt; 90 mm Hg at time of informed consent

          -  Do not resuscitate or do not intubate order

          -  Systemic fibrinolytic treatment within previous 7 days

          -  Inability to follow-up at 3 months

          -  Documented gastrointestinal bleeding within previous 30 days

          -  Active hemorrhage in any of the following sites at the time of enrollment:
             intraperitoneal, retroperitoneal, pulmonary, uterine, bladder, or nose.

          -  Head trauma causing loss of consciousness within previous 7 days

          -  Any history of hemorrhagic stroke

          -  Ischemic stroke within the past year

          -  Prior history of heparin-induced thrombocytopenia

          -  History of intraocular hemorrhage

          -  Intracranial metastasis

          -  Known inherited bleeding disorder, e.g., hemophilia

          -  Platelet count &lt; 50,000/uL

          -  Prothrombin time with an INR &gt;1.7

          -  Chest, abdominal, intracranial or spinal surgery within the previous 14 days

          -  Subacute bacterial endocarditis

          -  Pregnancy (positive pregnancy test)

          -  Prior enrollment in the study

          -  Current treatment with fondiparinux, dalteparin, a direct thrombin inhibitor or
             administration of a glycoprotein inhibitor within the previous 48 hours.

          -  Known pericarditis

          -  Allergy to heparins,or tenecteplase

          -  Elapsed time that would preclude drug or placebo administration within 24 hours after
             diagnosis

          -  Evidence of non-end stage kidney injury (creatinine clearance &lt; 30 ml/min without
             chronic hemodialysis treatment; chronic hemodialysis-treated patients are eligible)

          -  Preexisting end-stage cardiopulmonary disease (heart failure with left ventricular
             ejection fraction &lt;20%, known severe pulmonary hypertension or other lung disease
             causing permanent dependence upon oxygen)

          -  Any other condition that the investigator believes would pose a significant hazard to
             the subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey A Kline, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carolinas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2008</study_first_submitted>
  <study_first_submitted_qc>May 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2008</study_first_posted>
  <results_first_submitted>October 29, 2013</results_first_submitted>
  <results_first_submitted_qc>July 22, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 11, 2014</results_first_posted>
  <last_update_submitted>July 22, 2014</last_update_submitted>
  <last_update_submitted_qc>July 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Carolinas Healthcare System</investigator_affiliation>
    <investigator_full_name>Jeffrey Kline</investigator_full_name>
    <investigator_title>Director, Emergency Medicine Research</investigator_title>
  </responsible_party>
  <keyword>Pulmonary Embolism</keyword>
  <keyword>Tenecteplase</keyword>
  <keyword>Enoxaparin</keyword>
  <keyword>Thrombosis</keyword>
  <keyword>Fibrinolytics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenecteplase</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients enrolled from 8 hospitals from August 2008 until October, 2012. Genentech funded the study. Carolinas Medical Center was the prime contractor site and subcontracted 7 other hospitals.</recruitment_details>
      <pre_assignment_details>The investigator relocated to a new institution in July 2012, which led to insoluble problems with the subcontracts that forced early study closure.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Tenecteplase + Enoxaparin
Tenecteplase + Enoxaparin : Enoxaparin: 1 mg/kg within 12 hours before receiving tenecteplase.Subsequently, patients will receive 1 mg/kg enoxaparin SQ Q12 hours until discontinuation is clinically indicated.
Tenecteplase:will be administered using a tiered-dosing schedule according to patient weight: &lt;60Kg=30mg; ≥60Kg to &lt;70Kg=35mg; ≥70Kg to &lt;80Kg=40mg; ≥80Kg to &lt;90Kg=45mg; ≥90Kg=50mg</description>
        </group>
        <group group_id="P2">
          <title>Tenecteplase</title>
          <description>Saline + Enoxaparin
0.9% Saline + Enoxaparin : Enoxaparin: 1 mg/kg within 12 hours before receiving saline.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>see manuscript</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Tenecteplase + Enoxaparin
Tenecteplase + Enoxaparin : Enoxaparin: 1 mg/kg within 12 hours before receiving tenecteplase.Subsequently, patients will receive 1 mg/kg enoxaparin SQ Q12 hours until discontinuation is clinically indicated.
Tenecteplase:will be administered using a tiered-dosing schedule according to patient weight: &lt;60Kg=30mg; ≥60Kg to &lt;70Kg=35mg; ≥70Kg to &lt;80Kg=40mg; ≥80Kg to &lt;90Kg=45mg; ≥90Kg=50mg</description>
        </group>
        <group group_id="B2">
          <title>Tenecteplase</title>
          <description>Saline + Enoxaparin
0.9% Saline + Enoxaparin : Enoxaparin: 1 mg/kg within 12 hours before receiving saline.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="83"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="14"/>
                    <measurement group_id="B2" value="57" spread="14"/>
                    <measurement group_id="B3" value="55" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Cardiogenic Shock or Respiratory Failure From Pulmonary Embolism and Number of Patietnts With Major Hemorrhage</title>
        <time_frame>1,2,3,4, and 5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Tenecteplase + Enoxaparin
Tenecteplase + Enoxaparin : Enoxaparin: 1 mg/kg within 12 hours before receiving tenecteplase.Subsequently, patients will receive 1 mg/kg enoxaparin SQ Q12 hours until discontinuation is clinically indicated.
Tenecteplase:will be administered using a tiered-dosing schedule according to patient weight: &lt;60Kg=30mg; ≥60Kg to &lt;70Kg=35mg; ≥70Kg to &lt;80Kg=40mg; ≥80Kg to &lt;90Kg=45mg; ≥90Kg=50mg</description>
          </group>
          <group group_id="O2">
            <title>Tenecteplase</title>
            <description>Saline + Enoxaparin
0.9% Saline + Enoxaparin : Enoxaparin: 1 mg/kg within 12 hours before receiving saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Cardiogenic Shock or Respiratory Failure From Pulmonary Embolism and Number of Patietnts With Major Hemorrhage</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number With Functional Cardiopulmonary Limitations Assessed With a Composite Measurement (Six Minute Walk Distance, Right Ventricular Function and Quality of Life Score on the SF-36)</title>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Tenecteplase + Enoxaparin
Tenecteplase + Enoxaparin : Enoxaparin: 1 mg/kg within 12 hours before receiving tenecteplase.Subsequently, patients will receive 1 mg/kg enoxaparin SQ Q12 hours until discontinuation is clinically indicated.
Tenecteplase:will be administered using a tiered-dosing schedule according to patient weight: &lt;60Kg=30mg; ≥60Kg to &lt;70Kg=35mg; ≥70Kg to &lt;80Kg=40mg; ≥80Kg to &lt;90Kg=45mg; ≥90Kg=50mg</description>
          </group>
          <group group_id="O2">
            <title>Tenecteplase</title>
            <description>Saline + Enoxaparin
0.9% Saline + Enoxaparin : Enoxaparin: 1 mg/kg within 12 hours before receiving saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Number With Functional Cardiopulmonary Limitations Assessed With a Composite Measurement (Six Minute Walk Distance, Right Ventricular Function and Quality of Life Score on the SF-36)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number With Recurrent Venous Thromboembolism and/or Severe Post-phlebitic Syndrome</title>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Tenecteplase + Enoxaparin
Tenecteplase + Enoxaparin : Enoxaparin: 1 mg/kg within 12 hours before receiving tenecteplase.Subsequently, patients will receive 1 mg/kg enoxaparin SQ Q12 hours until discontinuation is clinically indicated.
Tenecteplase:will be administered using a tiered-dosing schedule according to patient weight: &lt;60Kg=30mg; ≥60Kg to &lt;70Kg=35mg; ≥70Kg to &lt;80Kg=40mg; ≥80Kg to &lt;90Kg=45mg; ≥90Kg=50mg</description>
          </group>
          <group group_id="O2">
            <title>Tenecteplase</title>
            <description>Saline + Enoxaparin
0.9% Saline + Enoxaparin : Enoxaparin: 1 mg/kg within 12 hours before receiving saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Number With Recurrent Venous Thromboembolism and/or Severe Post-phlebitic Syndrome</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Tenecteplase + Enoxaparin
Tenecteplase + Enoxaparin : Enoxaparin: 1 mg/kg within 12 hours before receiving tenecteplase.Subsequently, patients will receive 1 mg/kg enoxaparin SQ Q12 hours until discontinuation is clinically indicated.
Tenecteplase:will be administered using a tiered-dosing schedule according to patient weight: &lt;60Kg=30mg; ≥60Kg to &lt;70Kg=35mg; ≥70Kg to &lt;80Kg=40mg; ≥80Kg to &lt;90Kg=45mg; ≥90Kg=50mg</description>
        </group>
        <group group_id="E2">
          <title>Tenecteplase</title>
          <description>Saline + Enoxaparin
0.9% Saline + Enoxaparin : Enoxaparin: 1 mg/kg within 12 hours before receiving saline.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <description>led to death</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>intracranial hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeffrey Kline</name_or_title>
      <organization>Indiana University School of Medicine</organization>
      <phone>3172873004</phone>
      <email>jefkline@iupui.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

